NextCure (NXTC) is merging with privately-held Avere Therapeutics in an all-stock transaction, effectively becoming Avere Therapeutics and trading as 'AVRX'. This deal is coupled with a significant $320 million private placement, fully funding Avere's operations through key clinical trial readouts, and represents a strategic pivot for NextCure's shareholders into a new therapeutic area.
NextCure (NXTC) is undergoing a reverse merger with Avere Therapeutics, a privately-held biotech, in an all-stock transaction. This effectively transforms NextCure into Avere Therapeutics, which will trade under a new ticker, AVRX. The deal is highly significant as it includes a substantial $320 million private placement, providing Avere with funding through critical Phase 2b and Phase 3 trial milestones for its lead oral IL-23 program, AVR-001. For NextCure shareholders, this is a major strategic shift, offering them a contingent value right (CVR) for 90% of net proceeds from any future monetization of NextCure's legacy pipeline assets for two years, alongside their stake in the new combined company. The short-term implication for NXTC is likely a significant price adjustment reflecting the new entity's valuation and pipeline, while long-term, it offers exposure to a well-funded, experienced management team (from Akero Therapeutics) and a promising oral IL-23 therapy. The key opportunity for traders is the potential for growth in the new AVRX entity, driven by its strong funding and clinical pipeline.